

# Polymyositis Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/P502BB6D80EBEN.html>

Date: March 2022

Pages: 67

Price: US\$ 3,250.00 (Single User License)

ID: P502BB6D80EBEN

## Abstracts

Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. Its name means 'inflammation of many muscles' (poly- + myos- + -itis).

This report contains market size and forecasts of Polymyositis Treatment in Global, including the following market information:

Global Polymyositis Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Polymyositis Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Immunosuppressant Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Polymyositis Treatment include Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcam Corporation, Teva Pharmaceuticals, Novartis AG and Genentech, Inc.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Polymyositis Treatment

companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Polymyositis Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Polymyositis Treatment Market Segment Percentages, by Type, 2021 (%)

Immunosuppressant

Alkylating Agent

Immunoglobulin

Monoclonal Antibodies

Corticosteroids

Global Polymyositis Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Polymyositis Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinic

Others

Global Polymyositis Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Polymyositis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

## North America

US

Canada

Mexico

## Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

## Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

## South America

Brazil

Argentina

Rest of South America

## Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Polymyositis Treatment revenues in global market, 2017-2022  
(estimated), (\$ millions)

Key companies Polymyositis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Hospira, Inc.

Antares Pharma, Inc.

Medexus Pharma, Inc.

Fresenius SE & Co. KGaA

Mylan N.V.

Alcami Corporation

Teva Pharmaceuticals

Novartis AG

Genentech, Inc.

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Polymyositis Treatment Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Polymyositis Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL POLYMYOSITIS TREATMENT OVERALL MARKET SIZE**

- 2.1 Global Polymyositis Treatment Market Size: 2021 VS 2028
- 2.2 Global Polymyositis Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Polymyositis Treatment Players in Global Market
- 3.2 Top Global Polymyositis Treatment Companies Ranked by Revenue
- 3.3 Global Polymyositis Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Polymyositis Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Polymyositis Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Polymyositis Treatment Players in Global Market
  - 3.6.1 List of Global Tier 1 Polymyositis Treatment Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Polymyositis Treatment Companies

### **4 MARKET SIGHTS BY PRODUCT**

#### 4.1 Overview

4.1.1 by Type - Global Polymyositis Treatment Market Size Markets, 2021 & 2028

4.1.2 Immunosuppressant

4.1.3 Alkylating Agent

4.1.4 Immunoglobulin

4.1.5 Monoclonal Antibodies

4.1.6 Corticosteroids

#### 4.2 By Type - Global Polymyositis Treatment Revenue & Forecasts

4.2.1 By Type - Global Polymyositis Treatment Revenue, 2017-2022

4.2.2 By Type - Global Polymyositis Treatment Revenue, 2023-2028

4.2.3 By Type - Global Polymyositis Treatment Revenue Market Share, 2017-2028

### 5 SIGHTS BY APPLICATION

#### 5.1 Overview

5.1.1 By Application - Global Polymyositis Treatment Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinic

5.1.4 Others

#### 5.2 By Application - Global Polymyositis Treatment Revenue & Forecasts

5.2.1 By Application - Global Polymyositis Treatment Revenue, 2017-2022

5.2.2 By Application - Global Polymyositis Treatment Revenue, 2023-2028

5.2.3 By Application - Global Polymyositis Treatment Revenue Market Share, 2017-2028

### 6 SIGHTS BY REGION

6.1 By Region - Global Polymyositis Treatment Market Size, 2021 & 2028

#### 6.2 By Region - Global Polymyositis Treatment Revenue & Forecasts

6.2.1 By Region - Global Polymyositis Treatment Revenue, 2017-2022

6.2.2 By Region - Global Polymyositis Treatment Revenue, 2023-2028

6.2.3 By Region - Global Polymyositis Treatment Revenue Market Share, 2017-2028

#### 6.3 North America

6.3.1 By Country - North America Polymyositis Treatment Revenue, 2017-2028

6.3.2 US Polymyositis Treatment Market Size, 2017-2028

6.3.3 Canada Polymyositis Treatment Market Size, 2017-2028

6.3.4 Mexico Polymyositis Treatment Market Size, 2017-2028

#### 6.4 Europe

6.4.1 By Country - Europe Polymyositis Treatment Revenue, 2017-2028

- 6.4.2 Germany Polymyositis Treatment Market Size, 2017-2028
- 6.4.3 France Polymyositis Treatment Market Size, 2017-2028
- 6.4.4 U.K. Polymyositis Treatment Market Size, 2017-2028
- 6.4.5 Italy Polymyositis Treatment Market Size, 2017-2028
- 6.4.6 Russia Polymyositis Treatment Market Size, 2017-2028
- 6.4.7 Nordic Countries Polymyositis Treatment Market Size, 2017-2028
- 6.4.8 Benelux Polymyositis Treatment Market Size, 2017-2028

## 6.5 Asia

- 6.5.1 By Region - Asia Polymyositis Treatment Revenue, 2017-2028
- 6.5.2 China Polymyositis Treatment Market Size, 2017-2028
- 6.5.3 Japan Polymyositis Treatment Market Size, 2017-2028
- 6.5.4 South Korea Polymyositis Treatment Market Size, 2017-2028
- 6.5.5 Southeast Asia Polymyositis Treatment Market Size, 2017-2028
- 6.5.6 India Polymyositis Treatment Market Size, 2017-2028

## 6.6 South America

- 6.6.1 By Country - South America Polymyositis Treatment Revenue, 2017-2028
- 6.6.2 Brazil Polymyositis Treatment Market Size, 2017-2028
- 6.6.3 Argentina Polymyositis Treatment Market Size, 2017-2028

## 6.7 Middle East & Africa

- 6.7.1 By Country - Middle East & Africa Polymyositis Treatment Revenue, 2017-2028
- 6.7.2 Turkey Polymyositis Treatment Market Size, 2017-2028
- 6.7.3 Israel Polymyositis Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia Polymyositis Treatment Market Size, 2017-2028
- 6.7.5 UAE Polymyositis Treatment Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Hospira, Inc.

- 7.1.1 Hospira, Inc. Corporate Summary
- 7.1.2 Hospira, Inc. Business Overview
- 7.1.3 Hospira, Inc. Polymyositis Treatment Major Product Offerings
- 7.1.4 Hospira, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
- 7.1.5 Hospira, Inc. Key News

### 7.2 Antares Pharma, Inc.

- 7.2.1 Antares Pharma, Inc. Corporate Summary
- 7.2.2 Antares Pharma, Inc. Business Overview
- 7.2.3 Antares Pharma, Inc. Polymyositis Treatment Major Product Offerings
- 7.2.4 Antares Pharma, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)

- 7.2.5 Antares Pharma, Inc. Key News
- 7.3 Medexus Pharma, Inc.
  - 7.3.1 Medexus Pharma, Inc. Corporate Summary
  - 7.3.2 Medexus Pharma, Inc. Business Overview
  - 7.3.3 Medexus Pharma, Inc. Polymyositis Treatment Major Product Offerings
  - 7.3.4 Medexus Pharma, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
  - 7.3.5 Medexus Pharma, Inc. Key News
- 7.4 Fresenius SE & Co. KGaA
  - 7.4.1 Fresenius SE & Co. KGaA Corporate Summary
  - 7.4.2 Fresenius SE & Co. KGaA Business Overview
  - 7.4.3 Fresenius SE & Co. KGaA Polymyositis Treatment Major Product Offerings
  - 7.4.4 Fresenius SE & Co. KGaA Polymyositis Treatment Revenue in Global Market (2017-2022)
  - 7.4.5 Fresenius SE & Co. KGaA Key News
- 7.5 Mylan N.V.
  - 7.5.1 Mylan N.V. Corporate Summary
  - 7.5.2 Mylan N.V. Business Overview
  - 7.5.3 Mylan N.V. Polymyositis Treatment Major Product Offerings
  - 7.5.4 Mylan N.V. Polymyositis Treatment Revenue in Global Market (2017-2022)
  - 7.5.5 Mylan N.V. Key News
- 7.6 Alcam Corporation
  - 7.6.1 Alcam Corporation Corporate Summary
  - 7.6.2 Alcam Corporation Business Overview
  - 7.6.3 Alcam Corporation Polymyositis Treatment Major Product Offerings
  - 7.6.4 Alcam Corporation Polymyositis Treatment Revenue in Global Market (2017-2022)
  - 7.6.5 Alcam Corporation Key News
- 7.7 Teva Pharmaceuticals
  - 7.7.1 Teva Pharmaceuticals Corporate Summary
  - 7.7.2 Teva Pharmaceuticals Business Overview
  - 7.7.3 Teva Pharmaceuticals Polymyositis Treatment Major Product Offerings
  - 7.7.4 Teva Pharmaceuticals Polymyositis Treatment Revenue in Global Market (2017-2022)
  - 7.7.5 Teva Pharmaceuticals Key News
- 7.8 Novartis AG
  - 7.8.1 Novartis AG Corporate Summary
  - 7.8.2 Novartis AG Business Overview
  - 7.8.3 Novartis AG Polymyositis Treatment Major Product Offerings

7.8.4 Novartis AG Polymyositis Treatment Revenue in Global Market (2017-2022)

7.8.5 Novartis AG Key News

7.9 Genentech, Inc.

7.9.1 Genentech, Inc. Corporate Summary

7.9.2 Genentech, Inc. Business Overview

7.9.3 Genentech, Inc. Polymyositis Treatment Major Product Offerings

7.9.4 Genentech, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)

7.9.5 Genentech, Inc. Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Polymyositis Treatment Market Opportunities & Trends in Global Market

Table 2. Polymyositis Treatment Market Drivers in Global Market

Table 3. Polymyositis Treatment Market Restraints in Global Market

Table 4. Key Players of Polymyositis Treatment in Global Market

Table 5. Top Polymyositis Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Polymyositis Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Polymyositis Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Polymyositis Treatment Product Type

Table 9. List of Global Tier 1 Polymyositis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Polymyositis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Polymyositis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Polymyositis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Polymyositis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Polymyositis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Polymyositis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Polymyositis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Polymyositis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Polymyositis Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Polymyositis Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Polymyositis Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Polymyositis Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Polymyositis Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Polymyositis Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Polymyositis Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Polymyositis Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Polymyositis Treatment Revenue, (US\$, Mn),

2017-2022

Table 27. By Country - South America Polymyositis Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Polymyositis Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Polymyositis Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Hospira, Inc. Corporate Summary

Table 31. Hospira, Inc. Polymyositis Treatment Product Offerings

Table 32. Hospira, Inc. Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Antares Pharma, Inc. Corporate Summary

Table 34. Antares Pharma, Inc. Polymyositis Treatment Product Offerings

Table 35. Antares Pharma, Inc. Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Medexus Pharma, Inc. Corporate Summary

Table 37. Medexus Pharma, Inc. Polymyositis Treatment Product Offerings

Table 38. Medexus Pharma, Inc. Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Fresenius SE & Co. KGaA Corporate Summary

Table 40. Fresenius SE & Co. KGaA Polymyositis Treatment Product Offerings

Table 41. Fresenius SE & Co. KGaA Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Mylan N.V. Corporate Summary

Table 43. Mylan N.V. Polymyositis Treatment Product Offerings

Table 44. Mylan N.V. Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Alcam Corporation Corporate Summary

Table 46. Alcam Corporation Polymyositis Treatment Product Offerings

Table 47. Alcam Corporation Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Teva Pharmaceuticals Corporate Summary

Table 49. Teva Pharmaceuticals Polymyositis Treatment Product Offerings

Table 50. Teva Pharmaceuticals Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Novartis AG Corporate Summary

Table 52. Novartis AG Polymyositis Treatment Product Offerings

Table 53. Novartis AG Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Genentech, Inc. Corporate Summary

Table 55. Genentech, Inc. Polymyositis Treatment Product Offerings

Table 56. Genentech, Inc. Polymyositis Treatment Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Polymyositis Treatment Segment by Type in 2021
- Figure 2. Polymyositis Treatment Segment by Application in 2021
- Figure 3. Global Polymyositis Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Polymyositis Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Polymyositis Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Polymyositis Treatment Revenue in 2021
- Figure 8. By Type - Global Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 12. US Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Polymyositis Treatment Revenue Market Share, 2017-2028
- Figure 24. China Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Polymyositis Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Polymyositis Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Polymyositis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Hospira, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Antares Pharma, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Medexus Pharma, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Fresenius SE & Co. KGaA Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Mylan N.V. Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Alcam Corporation Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Teva Pharmaceuticals Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Novartis AG Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Genentech, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Polymyositis Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/P502BB6D80EBEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P502BB6D80EBEN.html>